October 14, 2020
From Andrea Maddox-Smith, CEO:
Today’s news that Merck has announced construction of a new manufacturing facility to significantly expand its production capacity for TICE® BCG is welcome news for bladder cancer patients. We appreciate Merck’s commitment to increase the supply of a treatment that is in such high demand for bladder cancer patients. The Bladder Cancer Advocacy Network will continue to work collaboratively and tirelessly with the medical research and pharmaceutical industries to improve outcomes for bladder cancer patients.